Privacy Policy
Your privacy is important to us. This Privacy Policy explains how we collect, use, and protect your information when you use our website.
Last Updated: September 25, 2026
Information We Collect
We may collect personal information that you voluntarily provide, including:
Name
Email address
Phone number
Any information submitted through contact or appointment forms
We may also collect non-personal data such as browser type, device information, and pages visited for analytics purposes.
How We Use Your Information
We use the collected information to:
Respond to inquiries and requests
Provide and improve our services
Communicate updates or important information
Analyze website performance and user experience
Cookies & Analytics
Our website may use cookies and similar technologies to enhance your browsing experience and analyze traffic. You can choose to disable cookies through your browser settings.
Data Protection
We take reasonable measures to protect your personal information from unauthorized access, disclosure, or misuse. However, no method of transmission over the internet is completely secure.
Third-Party Services
We may use trusted third-party tools (such as analytics or form services) to operate our website. These services only receive the information necessary to perform their functions and are obligated to protect your data.
Your Rights
You have the right to:
Request access to your personal data
Request correction or deletion of your data
Withdraw consent at any time
To exercise these rights, please contact us using the information below.
Children’s Privacy
Our website is not intended for children under the age of 13, and we do not knowingly collect personal information from children.
Changes to This Policy
We may update this Privacy Policy from time to time. Any changes will be posted on this page with an updated revision date.
Contact Us
If you have any questions about this Privacy Policy, please contact us at:
Email: biohybridd@gmail.com
FAQs
What is Bio-Hybrid Therapeutics developing?
Bio-Hybrid Therapeutics is developing biologic medications focused on allergic diseases, including Atopic Dermatitis, Rhinitis, IBS, and anaphylaxis-related allergic reactions.
What is BHT002D™?
BHT002D™ is Bio-Hybrid Therapeutics’ lead patent-pending biologic candidate for Atopic Dermatitis. It is intended to prevent allergic reactive symptoms caused by specific protein allergens.
Is BHT002D™ approved by the FDA?
BHT002D™ is set to begin clinical trials in Summer 2027.
Who is Bio-Hybrid Therapeutics designed to serve?
The primary audience includes healthcare providers, allergists, and immunologists. Secondary audiences include patients with severe or chronic allergic conditions, and tertiary audiences include biotech investors and research institutions.
What makes Bio-Hybrid Therapeutics different?
Bio-Hybrid Therapeutics is focused on prevention, precision, simplicity, and biologic innovation, with a brand voice that balances scientific rigor and human empathy.
